Study to Find Biomarkers Predicting Immune Side Effects in Cancer Patients Receiving Immune Checkpoint Inhibitor Treatment

What this Trial Is About

Cancer treatment has evolved from surgery, radiotherapy, and chemotherapy to include targeted therapies like tyrosine kinase inhibitors and immune checkpoint inhibitors ICPI, such as anti-CTLA-4 and anti-PD1. These ICPIs activate the immune system to fight tumors and can produce lasting responses, even with metastases. However, ICPIs may cause serious immune-related side effects called irAEs, including colitis, hepatitis, dermatitis, and thyroiditis, which can lead to treatment discontinuation or severe health issues. Detecting patients at risk for irAEs is important due to the growing use of ICPIs and their long-term effects. This study involves collecting blood samples to measure cytokine concentrations, including IL6, IL10, IL15, IL8, INFgamma, MCP-1, MIP 1 alpha, MIP 1 beta, sIL2R, and sIL6R, over a 6-month period. These measurements aim to identify biomarkers that predict immune-related adverse events in patients receiving ICPI treatment. The study includes patients undergoing anti-PD1 andor anti-CTLA-4 therapies in oncology, pneumology, dermatology, or gastroenterology departments. Participants will provide blood samples to monitor changes in specific cytokine levels from baseline during the study. Researchers will evaluate these variations to understand their association with irAEs. The study tracks these outcomes over six months, assessing immune markers to improve detection of patients at risk. The total participation involves follow-up and monitoring through blood collection at set intervals to gather data on immune responses and adverse events.

Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment